Neuroscience and Biobehavioral Reviews
Neuroscience and Biobehavioral Reviews
Neuroscience and Biobehavioral Reviews
Review
a r t i c l e
i n f o
Article history:
Received 14 May 2014
Received in revised form
18 September 2014
Accepted 28 October 2014
Available online 6 November 2014
Keywords:
Post-traumatic fatigue
Traumatic brain injury
Rehabilitation
Systematic review
a b s t r a c t
Background: Fatigue is common after traumatic brain injury (TBI). Its risk factors, natural history and
consequences are uncertain. Best-evidence synthesis was used to address the gaps.
Methods: Five databases were searched for relevant peer-reviewed studies. Of the 33 articles appraised,
22 longitudinal studies were selected. Results were reported separately based on their timing of baseline
assessment.
Results: All studies document changes in fatigue frequency and severity with time, irrespective of setting
or TBI severity. There is limited evidence for certain clinical and psychosocial variables as predictors of
fatigue severity at follow-up. Early fatigue severity predicted persistent post-concussive symptoms and
Glasgow outcome score at follow-up.
Conclusions: Fatigue is present before and immediately following injury, and can persist long term. The
variation in ndings supports the idea of fatigue in TBI as a nonhomogeneous entity, with different factors
inuencing the course of new onset or chronic fatigue. To decrease the heterogeneity, we emphasize the
need for agreement on a core set of relevant fatigue predictors, denitions and outcome criteria.
PROSPERO registry number: CRD42013004262.
2014 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/3.0/).
Abbreviations: APOE-4, apolipoprotein-4; BDI, Beck depression inventory; BFS, Barosso fatigue scale; CHART, Craig handicap assessment and reporting technique;
CNS, central nervous system; DRS, disability rating scale; FSS, fatigue severity scale; GCS, Glasgow coma scale; GOSE, Glasgow outcome scale-extended; GFI, global fatigue
inventory; HADS, hospital anxiety and depression scale; MFIS, modied fatigue impact scale; MFI, multidimentional fatigue inventory; mTBI, mild traumatic brain injury;
PRISMA, preferred reporting items for systematic reviews and meta-analyses; PCSC, post-concussion syndrome checklist; POMS, prole of moods scale; RCT, randomized
controlled trial; RPQ, Rivermead post-concussive questionnaire; SIGN, Scottish intercollegiate guidelines network; SF-36, 36-item short form health survey (from medical
outcomes study); TBI, traumatic brain injury; VAS, visual analog scale.
Corresponding author at: Toronto Rehabilitation Institute, 550 University Avenue, Rm 11207, Toronto, Ontario M5G 2A2, Canada. Tel.: +1 416 597 3422x7848;
fax: +416 946 8570.
E-mail addresses: [email protected] (T. Mollayeva), [email protected] (T. Kendzerska), [email protected] (S. Mollayeva),
[email protected] (C.M. Shapiro), [email protected] (A. Colantonio), [email protected] (J.D. Cassidy).
1
Tel.: +1 416 669 6759; fax: +1 416 946 8570.
2
Tel.: +1 416 978 1098; fax: +1 416 946 8570.
3
Tel.: +1 416 603 5800x5160; fax: +1 416 603 5292.
4
Address: Saunderson Family Chair in Acquired Brain Injury Research, Toronto Rehabilitation Institute, University of Toronto, 160-500 University Avenue, Toronto, Ontario
M5G 1V7, Canada. Tel.: +1 416 978 1098; fax: +1 416 946 8570.
5
Tel.: +45 6550 3471; fax: +45 2328 5051.
http://dx.doi.org/10.1016/j.neubiorev.2014.10.024
0149-7634/ 2014 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).
685
Background . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Methods/design . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
2.1.
Data sources and searches . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
2.2.
Inclusion criteria . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
2.3.
Study design . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
2.4.
Study review . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
2.5.
Data extraction and quality assessment . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
2.6.
Data synthesis . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
2.7.
Zero-time . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
2.8.
Missing data . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Results . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
3.1.
Literature search and quality assessment . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
3.2.
Study characteristics . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
3.3.
Studies with baseline assessment up to one month post-injury . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
3.4.
Studies with baseline assessment after one month post-injury . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
3.5.
Assessment of TBI . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
3.6.
Methods used for assessing fatigue . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
3.6.1.
Multi-item scales . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
3.6.2.
Single item assessment of fatigue . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
3.6.3.
Multiple measures of fatigue . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
3.7.
Overall predictors of fatigue . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
3.8.
The course of fatigue . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
3.9.
The course of fatigue, by injury severity . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
3.10.
Fatigue severity . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
3.11.
Impact of fatigue after TBI . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
3.12.
Associations of fatigue with other clinically important variables . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
3.12.1.
Studies with baseline assessment up to one month post-injury . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
3.12.2.
Studies with baseline assessment after one month post-injury . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
3.13.
Medications, drugs and alcohol . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Discussion . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
4.1.
Factors associated with fatigue . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
4.2.
Frequency, severity and course of fatigue in TBI . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
4.3.
Consequences of fatigue in TBI . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
4.4.
Medication effects . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
4.5.
Limitations . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
4.6.
Pitfalls and controversies . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Conclusions . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Authors contributions . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Acknowledgements . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Appendix A.
Supplementary data . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
References . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
685
686
686
686
686
686
686
703
703
703
703
703
706
706
706
706
706
706
707
707
707
707
707
707
709
709
709
709
710
710
710
710
711
711
712
712
714
714
714
714
714
Contents
1.
2.
3.
4.
5.
1. Background
Traumatic brain injury (TBI), dened as an alteration in brain
function, or other evidence of brain pathology, caused by an external force (Brain Injury Association of America, 2013), is among
the most serious, disabling neurological disorders in all societies
and expected to rank as the major cause of death and disability
by the year 2020 (World Health Organization, 2002). Over the past
decades, evidence has emerged citing fatigue as a common, longlasting problem after TBI (Belmont et al., 2006; Ponsford et al., 2011;
Middleboe et al., 1992). It is burdensome to patients, and is associated with poor outcomes (Belmont et al., 2006; Ponsford et al.,
2011). In a number of studies, over half of the patients making up
the TBI samples reported fatigues negative effect on social, physical
and cognitive functioning (Ziino and Ponsford, 2006) and participation in everyday activities (Cantor et al., 2008), and role in increased
work-related and other disabilities (McCrimmon and Oddy, 2006).
Estimates of the incidence of fatigue after TBI vary from 21% to
73%, depending on the characteristics of the studied population
(e.g. severity of injury, time since injury, sampling of patients, etc.)
and the method used to identify fatigue (e.g. single item or fatigue
scales) (Belmont et al., 2006; Ponsford et al., 2011; Middleboe et al.,
1992; Borgaro et al., 2005; Lidvall et al., 1974).
686
and follow-up treatments. Moreover, identifying the most important contributors to PTF can change the view on the interventions
necessary to deal with this signicant symptom. This systematic
review was performed with the following goals, all with respect to
patients with TBI: (1) to determine the prognostic factors associated with fatigue onset; (2) to describe the course of fatigue; and
(3) to describe the health consequences of fatigue.
2. Methods/design
were excluded. Further, case reports, pediatric studies, dissertations, and articles with no primary data were excluded. For more
information, we refer the reader to the protocol (Mollayeva et al.,
2013a).
2.3. Study design
All experimental intervention and effectiveness studies of longitudinal design and observational cohort- and case control-designed
studies were considered for this review.
Table 1
Summary of study characteristics, including details on study sample, design, methods and results pertaining to fatigue.
Reference
Country
Sample by
Sample size
Attrition
Age, sex (% M)
Time since injury (TSI)
Injury severity (IS)
Assessment time points/N
assessed (AT: t1 , t2 , etc.)
n = 51
Attrition: 0
Age: 31 13
Sex: 76% M
TSI: discharge 6 mos
post-injury
IS: GCS motor; PTA length;
degree cranial midline
shift: mod-sev
AT: baseline
t1 : 2.6 1.8 mos
t2 : 12.6 1.2 mos
t3 : 23.2 3.4 mos
Statistical method
rmANOVA: change
over time
Post hoc pairwise t
tests: signicant
variables
p-value = .01
Medications
NR*
*Study #2, same
population: at year 1
11% illicit drug users,
19% classied as
problem substance
users; at year 2 29%
classied as problem
substance users
Results
Fatigue denition
Frequencies, scores
Score changes:
BFS subscales: NS
GFI: signicant
decrease t1 ct2
(t42 = 5.4; p = .0018;
effect size = .58)
FSS: NS
Notes:
Fatigue total scores had
same pattern of
change: highest at t1 ,
lowest at t2 , slight
increase at t3
GFI at t1 : only score
comparable to other
populations with
signicant fatigue
BFS subscales:
low-mod fatigue; avg
scores below 50% of
max score for each
subscale (exception:
relieving factors)
Associations:
Increased fatigue
t1 t2 , more sleep
problems (PSQI)
decreased and stable
fatigue scores,
decreased PSQI
Increased fatigue,
decreased cognitive
functioning; decreased
fatigue-increased
cognitive functioning;
similar for general
functioning, motor
symptoms
Objective
Design
Follow-up (F/U)
Inclusion/exclusion criteria
(IC/EC)
687
688
Table 1 (Continued)
Reference
Country
Sample by
Objective
Design
Follow-up (F/U)
Inclusion/exclusion criteria
(IC/EC)
Sample size
Attrition
Age, sex (% M)
Time since injury (TSI)
Injury severity (IS)
Assessment time points/N
assessed (AT: t1 , t2 , etc.)
Statistical method
Medications
Results
Fatigue denition
Frequencies, scores
2-tailed tests of
signicance, = .05
Chi-square: group
differences
(categorical)
Univariate ANOVA:
group differences
(continuous)
Hierarchical linear
regression: variable
associations
NR
Pair-wise comparisons:
1: Lower mean score at
12 mos than other
injury group (p = .027)
2: Comparison NS
n = 18 TBI
2 groups: 1: PA; 2: control
Attrition: 0
Age: 37.7 2.3
Sex: NR
TSI:
1:40.8 14.7 mos
2:36.3 14.2 mos
IS:
Each group: 6 w/ left-sided
lesion proximity to frontal
pole; 1: 2 w/ damage to left
basal ganglia; 2:
2 w/damage to right
parietal occipital lobe
AT: BL
t1 : 8 wks
ANOVA: between,
within group
differences
Effect size: total
variance accounted for
by independent
variable
Fatigue denition: NR
POMS fatigue-inertia subscale
Mean fatigue subscale scores at
BL:
1: 1.4 1.1
2: 1.2 .6
Mean fatigue subscale scores at
t1 :
1: .5 .6
2: 1.3 .6
Effect size:
1: 1.00
2: .08
Within group
differences (BL t1 ):
1: signicant (F = 4.7,
p < .05)
2: NS
Between group
differences:
Fatigue NR; signicant
wrt total POMS score
(F = 5.7, p < .05)
n = 18
2 groups: 1: Tai Chi (9); 2:
control, waiting list for Tai
Chi (9)
Attrition: 0
Age:
F: 40.2 12.5, M:
51.2 8.7, Sex: 50% M
TSI: mean = 8.7 yrs
IS: NR
AT: Before
t1 : After (6 wks)
t-tests: within,
between group
differences at time
points
ANOVA: within,
between group
differences over time
periods
NR
Fatigue denition: NR
MOS SF-36 Vitality subscale
VAMS Tired mood state scale
(Tai Chi group only)
SF-36 Vitality: Before:
1: 47.1 18.2
2: 47.5 20.2
After:
1: 40.7 22.3
2: 38.8 4.4
VAMS Tired: Before:
1: 54.4 6.0
After:
1: 52.5 5.8
n = 126
Attrition: 25%
Age: 38.3 14.1
Sex: 63% M
TSI: 2 wks
IS: GCS: mild
AT: BL: 2 wks
post-injury/n = 126
t1 : 3 mos/n = 107
t2 : 6 mos/n = 107
t-tests, chi-square:
demographic, clinical
characteristics
Individual regression
analyses: cognitive,
emotional, behavioral
variables as covariates
with gender/age, PCS
outcome as dependent
variable
Logistic regressions
(LR): for signicant
variables from
individual regression
analyses
Stepwise backward LR:
derive models for 3, 6
mos
HosmerLemeshow
goodness of t
statistic: t of model
assessment
NR
Fatigue denition: NR
RPQ (including fatigue, sleep
disturbance items)
RPQ: fatigue, sleep disturbance
most commonly reported
symptoms are 3 and 6 mos
port-mTBI
Fatigue frequencies: NR
From bar graph:
Fatigue at 3 mos 33%, at 6
mos 28%
Sleep disturbance at 3 mos
27%, at 6 mos 24%
NR
689
690
Table 1 (Continued)
Hutchinson et al.
(2009)
CA
University sports
Objective
Design
Follow-up (F/U)
Inclusion/exclusion criteria
(IC/EC)
Sample size
Attrition
Age, sex (% M)
Time since injury (TSI)
Injury severity (IS)
Assessment time points/N
assessed (AT: t1 , t2 , etc.)
n = 53
3 groups: 1: mTBI (20); 2:
MSI (14); 3: CTL (19)
Attrition: 0
Age:
1: 20.1 1.8
2: 19.2 2.3
3: 21.6 1.6
Sex:
1: 60% M
2: 86% M
3: 47% M
TSI:
1: 96 hrs
IS:
1: concussion (mTBI) by
team physicians, therapists
AT: BL
t1 , t2 , t3 : 3 d*
*Nonconsecutive over 2
wks
Statistical method
Descriptive:
demographic variables,
mood scales
Cronbach alpha: scale
reliability
ANOVA: group
differences on POMS
subscales at BL;
physical characteristics
StudentNewmanKeuls
multiple-range test
(.05): F/U means
TukeyKramer
correction for type I
error
Medications
NR
Results
Fatigue denition
Frequencies, scores
Fatigue denition: NR
POMS fatigue subscale:
Reliability: .863
Scores:
Main effects: NS
Signicant interacting effect
for fatigue (F(6, 150), 10.11;
p < .001)
Difference at t1 : signicant for
1 (increase) vs. 2, 3
Reference
Country
Sample by
n = 51 (46*)
2 groups: 1: modanil rst
(27 (22*)); 2: placebo rst
(24)
*5 participants in group 1
withdrew
Demographic/clinical
characteristics reported for
n = 51**
**NS imbalances to affect
trial results
Attrition: 0
Age: 38.3 12.2
Sex: 69% M
TSI: 5.8 5.0 yrs
IS: GCS: mild (25.5%), mod
(23.5%), sev (51%)
AT (n = 46): BL
t1 : wk 4
t2 : wk 10
t-tests, chi-square:
continuous and
categorical,
respectively: BL
differences in
demographic/clinical
characteristics
between groups
Paired t-test: crude tx
effects
2-sample t-tests:
within group tx effects
Linear mixed-effects
regression: 4-wk
change in each of 2
periods for all
participants
Secondary analyses: tx
effects on secondary
end-points and at 10
wks
MFIS
FSS
SF-12 (fatigue item)*
*Fatigue NR separately
FSS, MFIS high scores
Scores: BL; t1 ; t2 :
FSS:
1: 45.2 11.8; 39.4 15.6;
37.13 18.33
2: 44.46 12.17; 37.7 12.55;
36.91 14.08
MFIS:
1: 46.56 19.28;
38.65 16.09; 35.63 20
2: 47.17 15.53;
36.45 15.03; 33.55 18.16
Group medication switch
modanil to placebo, vice
versa:
FSS:
1 (placebo): 35.92 16.82;
33.74 16.16; 30.95 16.25
2 (modanil): 38.17 15.23;
31.38 10.66; 28.90 14.03
MFIS:
1: 36.27 17.67;
37.74 17.51; 31.20 19.44
2: 39.73 20.82;
28.91 19.06; 28.27 16.06
1 vs. 2:
modanil-placebo
scores:
Change wk 4-BL (p
value):
FSS: 2.33 12.96 (.54)
MFIS: 5.68 14.79 (.21)
Wk 10-BL:
FSS: .44 15.31 (.92)
MFIS: 4.03 16.93 (.43)
Group medication
switch modanil to
placebo, vice versa:
Wk 4-BL:
FSS: 2.55 11.07 (.45)
MFIS: 10.9 15.93
(.03)
Wk 10-BL:
FSS: 3.70 14.60 (.43)
MFIS: 8.07 16.61
(.14)
Notes:
Participants suggested
fatigue measures used
in study do not
accurately reect
fatigue experienced by
persons with TBI
691
692
Table 1 (Continued)
Reference
Country
Sample by
Objective
Design
Follow-up (F/U)
Inclusion/exclusion criteria
(IC/EC)
Sample size
Attrition
Age, sex (% M)
Time since injury (TSI)
Injury severity (IS)
Assessment time points/N
assessed (AT: t1 , t2 , etc.)
Statistical method
Medications
Results
Effect of modanil on
posttraumatic EDS and fatigue
Prospective, double-blind,
randomized,
placebo-controlled, pilot
F/U: 6 wks
IC*: presence of
fatigue/EDS/both since injury
* Patients from earlier study
(Baumann et al., 2007)
admitted for closed mild-sev
TBI to surgical intensive care
unit
EC: patients with neurologic,
psychiatric, other disorders,
medications that may cause
SWD; signicant SWD other
than posttraumatic vigilance
impairment at BL; chronic
sleep deprivation
n = 20
2 groups: 1: modanil
(10); 2: placebo (10)
Attrition: 0
Age:
1: 37 9
2: 43 19
Sex:
1: 80% M
2: 90% M
TSI:
1: 1.8 .9 yrs
2: 2 1.2 yrs
IS: GCS: mild-sev
AT: BL
t1 : 6 wks
Pearson, Spearman
correlation analyses;
two-tailed t-tests;
MannWhitney U
tests; multivariate
regression analyses
Modanil
(100200 mg)
Interfering medication
use as part of exclusion
criteria; caffeine, other
drugs not allowed
during course of study
FSS > 4
BL: frequency of fatigue
diagnosis:
1: .8
2: .8
BL: FSS
1: 5 1.4
2: 4.6 .8
t1 (p = 0.07):
1: .8 1
2: .0 .6
Notes:
Overall subjective
estimation of vigilance
impairment
amelioration:
1: much better (0%);
better (30%);
somewhat better
(30%); unchanged
(30%); worse (10%)
2: much better (10%);
better (10%);
somewhat better
(10%); unchanged
(70%); worse (0%)
Prevalence, characteristics of
post-traumatic sleep-wake
disorders (SWD)
Prospective, longitudinal,
clinical
F/U: 3 yrs
IC: acute, rst TBI; no SWD,
psychiatric/neurological
disorders prior; admitted
immediately after injury
EC: NR
n = 51
*Studied at 6 mos wrt SWD
(n = 65, Baumann et al.,
2007)
Attrition: 21.5%
Age: 40 16
Sex: 84% M
TSI: 3 yrs
IS: GCS: mild (42%), mod
(22%), sev (38%)
AT:
t1 : 6 mos/n = 65 (Baumann
et al., 2007)
t2 : 3 yrs/n = 51 (this study)
Correlation analyses
t-tests: parametric
MannWhitney U
tests: non-parametric
One-way ANOVA:
group differences
McNemar test:
repeated dichotomous
measures
3 (antiepileptic drugs),
1 (zopidem for sleep)
NR
Fatigue denition
Frequencies, scores
n = 10
Attrition: 33.3%
Age: 43 8
Sex: 60% M
TSI: 42 33 mos
IS: PTA: 8 10 d
AT: BL
t1 : 3 mos
Non-parametric
Wilcoxon: statistical
signicance of changes
by donepezil therapy
t1 : mean score:
126.1 32.3 (p = .92,
Z = .10)
Notes:
Subjects self-report
post-tx: 80% reported
medication-related
improvement in 1
cognitive/affectivebehavioral domain
40% wrt fatigue
dominating
improvement
Subjective fatigue
improvement did not
correlated with
decrease in fatigue
score only 2 patients
showed notable
decrease in score
2 patients that did not
report subjective
improvement had
notable decrease in
fatigue score
Discrepancies may be
result of varying
denitions of fatigue
693
Reference
Country
Sample by
Objective
Design
Follow-up (F/U)
Inclusion/exclusion criteria
(IC/EC)
Sample size
Attrition
Age, sex (% M)
Time since injury (TSI)
Injury severity (IS)
Assessment time points/N
assessed (AT: t1 , t2 , etc.)
Statistical method
Medications
694
Table 1 (Continued)
Results
Fatigue denition
Frequencies, scores
n = 100 CC
Attrition: 0
Stats:
PTA (min):
<1: 17%; 15: 34%; 645:
29%; >45: 20%
Age: 33 y (av)
Sex: 69% M
TSI: <24 h
IS: PTA: mild-sev
AT: post-injury:
t1 : 2 d
t2 : 6 d
t3 : 14 d
t4 : 30 d
t5 : 90 d
Descriptive: summary
of all variables
Chi-square: discrete
variable differences
between PCS- and
C-groups
Phi coefcients for
symptoms clustering
NR
PCS-symptom questionnaire
Fatigue frequencies by PCS list:
t1 : 7%
t2 : 5%
t3 : 10%
t4 : 8%
t5 : 10%
Fatigue frequency at any given
time point 12%
Clusters unstable,
varying in extent and
character across time
points:
t1 :
1: headaches,
dizziness, fatigue,
concentration
impairment (largest)
2: memory
impairment, sensitivity
to light
t2 :
1: headaches, dizziness
2: headaches, fatigue
3: dizziness, fatigue
t3 :
1: headaches, fatigue,
dizziness
2: anxiety,
concentration
impairment
t4 :
1: anxiety, fatigue,
headaches
t5 :
1: headaches, anxiety
2: dizziness,
concentration
impairment
3: fatigue, anxiety
4: fatigue, headaches
MannWhitney U
tests: non-normal
continuous data
Chi-square/Fishers
exact tests: categorical
data
Bonferroni adjustment:
multiple comparisons
p = .05
Multilevel logistic
regression:
relationship between
stable patient
characteristics and
multiple
measurements
NR
Rivermead Post-Concussional
Questionnaire (RPQ);
Rivermead Head Injury F/U
Questionnaire (RHFUQ*): both
feature fatigue item
*Administered only at t4
RPQ score classication:
symptom resolution (1); mild
(2); moderate (3); severe (4)
RPQ fatigue frequencies:
t1: mTBI: 66.8%
(calculated from symptom load
bar graph)
t4 :
mTBI: 21%
Control: 11%
t1 t4 : signicant
decrease
Investigate type of
psychosocial difculties
associated with head injury
(HI) at 1mos and 12 mos
post-injury; whether degree of
psychosocial impairment
relate to HI severity
Prospective cohort
F/U: 1 mo, 12 mos post-injury
IC: HI; LOC and PTA > 1 h, or obj
evidence of cerebral trauma;
trauma required hospital
admission; 1560 yrs
EC: previous CNS insult or
involvement (e.g. epilepsy, HI,
alcoholism, mental
retardation); psychiatric
disorder
2 by 2 Chi-square tests
MannWhitney U tests
comparison of change
with time
KruskalWallis
distribution-free
analysis of variance;
post hoc comparison
according to Tukeys
method for
unequal-sized groups
NR
Prior history of
epilepsy, alcoholism,
mental retardation as
part of exclusion
criteria
A signicant reduction
in the number of
fatigue endorsed from
1 mo to 12 mos
post-injury (p < .001)
Signicant difference
between cases and
controls at 1 mo but
not at 12 mos
post-injury
n = 62 mTBI; 58 TC
Attrition: 0
Stats for TBI:
Age: 35.7 14.5
Sex: 67.7% M
TSI: 4.8 3.1 d
IS: GCS: mild
AT: post-injury:
t1 : 14 d
t2 : 3 mos
MannWhitney U
tests: non-normal
continuous data
Chi-square/Fishers
exact tests: categorical
data
Bonferroni adjustment:
multiple comparisons
p = .05
Multilevel logistic
regression:
relationship between
stable patient
characteristics and
multiple
measurements
Opiate administration
at t1 /t2 (n):
mTBI (37/62)
Control (37/58)
Marijuana use:
mTBI: 24.4%
Control: 19%
AUDIT alcohol screen
mTBI = 6.4 6.8; 8
hazardous alcohol use
indicator
At least 1 subs use
disorder: 12.5%
Fatigue symptom
frequencies (3 on
PCSC):
Absent at t2 :
mTBI: 24.2%
Control: 31%
Difference in frequency
between mTBI and
controls in
presence/absence at
t1 /t2 of fatigue: NS
695
696
Table 1 (Continued)
Reference
Country
Sample by
Sample size
Attrition
Age, sex (% M)
Time since injury (TSI)
Injury severity (IS)
Assessment time points/N
assessed (AT: t1 , t2 , etc.)
Statistical method
Chi-square w/ Yates
correction:
between-group
symptom comparison
2-Sided t test: VAS
score comparison
Multiple regression:
headache, cognitive
dysfunction VAS scores
as dependent,
demographic
characteristics as
independent
Medications
NR
Prior history of alcohol
abuse, drug abuse as
part of exclusion
criteria
Alcohol intolerance
31% at 3 mos
post-injury, 31% at 1 yr
post-injury
Results
Fatigue denition
Frequencies, scores
NR
Mickeviciene et al.
(2004)
LT
Hospital emergency
ward
Objective
Design
Follow-up (F/U)
Inclusion/exclusion criteria
(IC/EC)
n = 159
Attrition: 14.1%; 10.6%
Age: 35.9 15.6
Sex: 64% M
TSI: 1 wk; 10 d
IS: GCS: mild
AT: post-injury
BL/n = 263
t1 : 3 mos/n = 159
t2 : 6 mos/n = 159
Pearson correlation
coefcients: primary
dependent variables,
fatigue prevalence,
severity, energy,
depression, anxiety
associations
One-way ANOVA:
fatigue prevalence,
severity, energy change
Hierarchical
regression: t2 fatigue
severity with t1 fatigue
severity, depression,
anxiety
Receiver operating
characteristic curve:
sensitivity, specicity
of fatigue item on RPQ
in distinguishing those
w/ and w/o
pathological fatigue by
FSS at t2
NR
Regular intake of
psychoactive drugs,
history of drug abuse
as part of exclusion
criteria
FSS (severity)
RPQ fatigue item (prevalence)
SF-36v2 Vitality Subcale
FSS cut-off = 3.7
RPQ fatigue prevalence
frequency of item rating 2
(max 4)
SF-36v2 Vitality high
score = low fatigue (max 100)
Frequencies:
BL:
FSS: 54.1%
RPQ: 67.3%
t1 :
FSS: 35.8%
RPQ: 29.6%
t2 :
FSS: 34%
RPQ: 26.4%
Scores:
BL:
FSS: 3.99 1.53
RPQ: 2.09 1.24
SF-36v2 Vitality: 46.57 24.72
t1 :
FSS: 3.3 1.4
RPQ: 1.0 1.1
SF-36v2 Vitality: 60.2 19.7
t2 :
FSS: 3.2 1.4
RPQ: .96 1.1
SF-36v2 Vitality: 62.1 20.2
Correlations between
measures at time points
(p .000, unless otherwise
indicated):
FSS BL w/: FSS t1 : .53; FSS t2 :
.49; RPQ BL: .57; RPQ t1 : .30;
RPQ t2 : .38; SF-36v2 BL: NS;
SF-36v2 t1 : .42; SF-36v2 t2 : .4
FSS t1 w/: FSS t2 : .76; RPQ BL:
.16 (p .05); RPQ t1 : .45; RPQ
t2 : .5; SF-36v2 BL: NS; SF-36v2
t1 : .66; SF-36v2 t2 : .39
FSS t2 w/: RPQ BL: .2 (p .05);
RPQ t1 : .4; RPQ t2 : .62; SF-36v2
BL: NS; SF-36v2 t1 : .56;
SF-36v2 t2 : .59
Within-subject effects
BL-t2 (p < .0005):
FSS: F2,157 = 23.60;
2 = .23
RPQ: F2,157 = 60.556;
2 = .44
SF-36v2 Vitality:
F2,157 = 17.573; 2 = .18
Notes:
RPQ fatigue item
unsatisfactory for
prediction of
pathological fatigue
post-mTBI
Prevalence, severity,
predictors, covariates of fatigue
in persons with mTBI
Longitudinal prospective
F/U: 3, 6 mos post-injury
IC: patients presenting to
hospital with mild closed head
injury; GCS 1315;
LOC < 20 min; PTA < 24 h
EC: abnormal CT scan; regular
admission of psychoactive
drugs/history drug abuse;
central neurological
disorder/psychiatric condition;
skull/facial fractures/multiple
trauma/other major trauma
697
Reference
Country
Sample by
698
Table 1 (Continued)
Objective
Design
Follow-up (F/U)
Inclusion/exclusion criteria
(IC/EC)
Sample size
Attrition
Age, sex (% M)
Time since injury (TSI)
Injury severity (IS)
Assessment time points/N
assessed (AT: t1 , t2 , etc.)
Statistical method
Medications
Results
Fatigue denition
Frequencies, scores
Report on post-concussive
symptoms and associated
cognitive, psychological,
functional outcomes in persons
with uncomplicated mTBI
Prospective
F/U: 1 wk, 3 mos post-injury
IC: admitted to emergency and
trauma center;
trauma/accelerationdeceleration movement to
head w/ LOC < 30 min,
PTA < 24 h, GCS 1315 in last
24 h; 18 yrs; English-speaking
EC: general anesthesia after
injury; breath alcohol
>.05 mg/L at recruitment;
under inuence of illicit drug
at injury; focal neurological
signs/seizures and/or
intracerebral abrnormalities
based on CT; dominant upper
limb injury disabling from use
of computer mouse; spinal
precautions, cannot sit upright;
previous cognitive impairment,
neurological illness, major
alcohol/drug abuse, other
psychiatric impairment
affecting daily functioning; not
available for F/U
Narcotic analgesics by
self-report:
BL: 62.6% mTBI, 44% TC
t1 : 18.2% mTBI, 21.1%
TC
t2 : 2.2% mTBI, 2.5% TC
NA
Schoenberger et al.
(2001)
US
Tx seekers/patients of
neurologists/rehabilitation
clinics
n = 12; 2 groups: 1:
immediate tx; 2: waitlist
control
Attrition: 0
Age: 2153
Sex: 16.7% M
TSI: 36 mos21 yrs; mean:
7.7 yrs
IS: mild (75%); mod sev
(25%); PTA (self-report):
41.7%; LOC: 127 d
AT:
t1 : 1: pre-tx; 2: BL
t2 : 1: post-tx; 2: pre-tx
t3 : 1: 3 mos post-tx; 2:
post-tx
t4 : 1: NA; 2: 3 mos post-tx
ANCOVAs:
between-group
ANOVAs:
within-group; changes
over time
p = .05 (not adjusted for
multiple tests)
Change in medication
with tx: NA (33.3%);
eliminated (25%);
decreased (16.7%); no
change (25%)
Between-group
comparison of MFI
scores: total (F = 3.68,
p < .1); general (F = 8.04,
p < .05); physical
(F = 2.88); mental
(F = 9.10, p < .05);
reduced activity
(F = .24); reduced
motivation (F = 1.99)
Changes in MFI scores:
total (F = 8.43, p < .01);
general (F = 6.5, p < .01);
physical (F = 4.02,
p < .05); mental
(F = 14.68, p < .001);
reduced activity
(F = 3.48, p < .1);
reduced motivation
(F = 2.72, p < .1)
Signicant differences
(p < .05):
Pre-post, F/U: total,
general, mental
699
700
Table 1 (Continued)
Reference
Country
Sample by
Sample size
Attrition
Age, sex (% M)
Time since injury (TSI)
Injury severity (IS)
Assessment time points/N
assessed (AT: t1 , t2 , etc.)
Statistical method
Parametric statistics
(Pearson) chi square:
categorical variables
ANOVA:
between-severity
group comparison
Multiple regression:
demographic, IS
predictors
Principal components
analysis w/ varimax
rotation:
neuropsychological
variable assessment at
t2 (to reduce predictors
in multiple regression)
Bonferroni corrections:
signicant tests w/
multiple comparisons
Post hoc: cognitive
functioning in mild TBI
p < .05 (2-tailed)
Medications
At t2 , drug/alcohol use
by Alcohol use
disorders identication
test
Alcohol >once/mo
(chi(8) = 24.1, p < .01):
mild, mod (48%); sev
(27%)
n = 106
Alcohol and/or drugs
23/wk: 13%;
4/wk: 7%
Results
Fatigue denition
Frequencies, scores
NR
Notes:
Less fatigue predicts
better outcome
No effects of sex,
education, TBI severity
on fatigue at t2
Sigurdardottir et al.
(2009)
NO
Level I trauma center
Objective
Design
Follow-up (F/U)
Inclusion/exclusion criteria
(IC/EC)
n = 31 mTBI; 62 controls
Attrition: 0
Stats for mTBI:
Age (at entry): 55.2 13.6
Sex: 58.1% M
TSI (n = 18):
(injury-post-seccion):
19.7 14.5 mos
IS (self-report, conrmed
w/ criteria): mild
AT:
BL: pre-injury (previous
study)
F/U: post-injury
Controls: 1st, 2nd
assessments from previous
study
McNemars test:
differences pre- to
post-injury; for
controls, differences
1st to 2nd assessment
Fishers exact test:
between-group
comparison (i.e. mTBI
vs. controls)
NR
Fatigue frequency
within-group change:
mTBI: signicant
(p < .05)
Control: NS
n = 67
Attrition: 0
Age: 33.2 14.7
Sex: 64.2% M
TSI: 12 h post-injury at
hospital admission
IS: GCS mean: 12.6 (range
914); PTA mean:
7.8 7.3; range 130 d)
Mild: 64.2%
Mod: 35.8%
AT: post-injury:
t1 : 1 mos
t2 : 3 mos
t3 : 6 mos
t4 : 12 mos
Students
t/MannWhitney U
tests: where
appropriate
Pearsons correlation
coefcients:
independent measure
associations
analysis:
interobserver scoring
Chi-square w/
correction for
continuity: frequencies
Multivariate regression
by stepwise backward
method
Outcome variables
distribution: normal
for scales w/ 4 points;
all else categorical
NR
History of addiction to
alcohol or drugs as part
of exclusion criteria
Alcohol intolerance at
1, 3, 6 mos and 1
year = 6, 11, 17 and
20%, respectively
Fatigue as complaint on
symptoms checklist
Fatigue frequencies at time
points:
t1 : 57%
t2 : 61%
t3 : 45%
t4 : 45%
At all time points, features as
1/6 most frequent complaints
No correlation between injury
characteristics and complaints
at all time points
NR
701
702
Table 1 (Continued)
Reference
Country
Sample by
Sample size
Attrition
Age, sex (% M)
Time since injury (TSI)
Injury severity (IS)
Assessment time points/N
assessed (AT: t1 , t2 , etc.)
Statistical method
Chi-square:
associations of PCS
items in groups 1 and 2
Logistic regression:
predictors of mTBI w/
PPCS
p < .05
Medications
NR
Results
Fatigue denition
Frequencies, scores
NR
APOE 4 apolipoprotein-4; BDI, Beck depression inventory; BFS, Barroso fatigue scale; BL, baseline; CNS, central nervous system; CPCS, checklist for post-concussion syndrome; CT, computed tomography; d, day; ED, emergency
department; IC/EC, inclusion/exclusion criteria; IS, injury severity; ISS, injury severity score; FSS, fatigue severity scale; FNS, exyx neurotherapy system; F/U, follow-up; GCS, Glasgow coma scale; GOSE, Glasgow outcome
scale-extended; GFI, global fatigue inventory; LOC, loss of consciousness; MFIS, modied fatigue impact scale; MRI, magnetic resonance imaging; MHI, mild head injury; mTBI, mild traumatic brain injury; mos, months; NR, not
reported; NS, not signicant; PCS, post-concussion syndrome; PCSC, post-concussion syndrome checklist; POMS, prole of moods scale; PPCS, persistent post concussive syndrome; PTA, post traumatic amnesia; RPQ, Rivermead
post-concussive questionnaire; PSQI, Pittsburgh sleep quality index; SF-36, 36-item short form health survey (from medical outcomes study); TC, trauma controls; TBI, traumatic brain injury; tx, treatment; TSI, time since injury;
SSRI, selective serotonin reuptake inhibitor; VAS, visual analog scale; wks, weeks; yrs, years.
Objective
Design
Follow-up (F/U)
Inclusion/exclusion criteria
(IC/EC)
703
Table 2
Summary of reported predictors of fatigue.
Study
FSS
Frequency measure (i.e. score 3.7 indicates fatigue)
RPQ fatigue item
Frequency measure (i.e. symptom rating 2 indicates
fatigue)
MOS SF-36v2 Vitality subscale
Severity measure (i.e. low score indicates more fatigue)
Fatigue question
Frequency measure (i.e. answer yes to question Do
you often feel fatigued? indicates fatigue)
NS
Sex (p = .762)
Age (p = .507)
Education (p = .77)
Prior drug/alcohol treatment (p = .382)
Motor vehicle crash (p = .444)
Injury type (p = .792, p = .427)
Predictor of severity at 3 mos
Severity at wk 1 (FSS) (R = 0.53; p < .000)
Predictor of severity at 6 mos
Severity at wk 1 (R = 0.49; p < .000)
Severity at 3 mos (R = 0.76; p < .000)
Depression at 3 mos (B = .12; SE = .04; = .25; p < .0000)
Anxiety at 3 mos (B = .01; SE = .03; = .04; p = .610)
Predictor of frequency post-injury
APOE 4 genotype (p = .02)
APOE 4, apolipoprotein-4; MOS SF-36v2 NS, not signicant 36-item short form health survey vitality subscale (from medical outcomes study); FSS, fatigue severity scale;
RPQ, Rivermead post-concussive questionnaire; wk, week.
(i.e. untreated group) data and no effect data (i.e. intervention has
not effect) were utilized to address the second research objective
(i.e. to determine the course of fatigue) in patients with TBI.
Study quality was independently assessed by two reviewers (TM
and TK), using guidelines developed by Hayden et al. (2006) for
assessment of prognostic studies (Table 4). The appraisal was performed in two steps. First, the items related to six potential sources
of bias (i.e. study participation and attrition, associated factors and
outcome measurements, confounding measurement, and analyses)
were assessed, then presence of potential biases was judged Yes,
Partly, No, or Unsure. To summarize the level of evidence,
we used a system similar to the Scottish Intercollegiate Guidelines
Network (SIGN) methodology (SIGNPG, 2013): (i) +++ when all or
most of the quality criteria proposed by Hayden et al. were fullled
(i.e. allowing one Partly while appraising all potential sources of
bias); (ii) ++ when the majority of criteria were fullled; (iii) +
when few criteria were fullled (i.e. at least one Yes). Additionally, as proposed by SIGN, studies with retrospective data collection
did not receive a ++ rating, as this design is weaker than prospective data collection. We refer to group (i) as high quality studies;
group (ii) as good quality studies; and group (iii) as fair quality
studies.
2.7. Zero-time
3. Results
3.1. Literature search and quality assessment
Of 2745 articles identied, 33 were selected for full-text review
(Lidvall et al., 1974; Ponsford et al., 2012; De Leon et al., 2009;
Lundin et al., 2006; Meares et al., 2011; Mickeviciene et al., 2004;
704
Table 3
Summary of reported consequences of fatigue.
Study
FSS
Frequency measure (i.e. score 3.7 indicates fatigue)
RPCQ fatigue item
Frequency measure (i.e. symptom rating 2 indicates
fatigue)
RPSQ
Presence/problem status of 16 post-concussional
symptoms
FSS
Severity measure (i.e. higher score indicates more
fatigue)
Full sample
Predictor of GOSE
Fatigue severity at 3 mos (R2 = .61, p < .001)
Predictor of GOSE at 12 mos
Fatigue severity by FSS (B = .13; SE = .04; = .25; p < .001)
mTBI
Predictor of GOSE at 12 mos
Fatigue severity by FSS (R2 = .47, p < .01)
Moderate/severe TBI
Fatigue severity by FSS (R2 = .58, p < .001)
FSS, fatigue severity scale; GOSE, Glasgow Outcome Scale-Extended; mTBI, mild traumatic brain injury; mos, months; PCS, post-concussion syndrome; RPCSQ, Rivermead
post-concussion symptom questionnaire; wk, week.
Norrie et al., 2010; van der Naalt et al., 1999; Yang et al., 2009;
McLean et al., 1993; Sundstrom et al., 2007; Hutchinson et al., 2009;
Sigurdardottir et al., 2009; Kempf et al., 2010; Driver and Ede, 2009;
Gemmell and Leathem, 2006; Bushnik et al., 2008a; Jha et al., 2008;
Kaiser et al., 2010; Khateb et al., 2005; Schoenberger et al., 2001;
Hou et al., 2012; Bhambhani et al., 2008; Bateman et al., 2001;
Bushnik et al., 2008b; Cooper et al., 2009; Hillier et al., 1997; Wiart
et al., 2012; Kim et al., 1999; Haboubi et al., 2001; Olver et al., 1996;
Rees and Bellon, 2007) and 22 were included in the nal review
Table 4
Quality assessment of studies using guidelines developed by Hayden et al. (2006).
Study
Study participation
Time-zero
Study
attrition
Prognostic
factor
Outcome
Confounding
measurement
and account
Analysis
Reason for
exclusion
Overall
assessment
No
No
Partlye
Partlye
No
Partlye
No
Partlye
No
Partlye
No
No
No
No
No
No
No
Partlye
No
No
No
No
Yesi
No
Yesi
Yesi
Yesi
No
Yesi
Yesi
Yesi
Yesi
No
No
No
No
No
No
No
Yesi
Yesi
No
No
No
Yesd
Partlya
No
Not sure
No
Not sure
No
No
No
Partlya
No
No
No
Partlya
No
Partlya
Partlya
Not sure
No
No sure
No
Partlya
NA
No
NA
NA
No
NA
Partlyg
Not sure
NA
NA
NA
NA
NA
No
NA
No
NA
NA
No
No
NA
No
No
No
No
No
No
No
No
No
No
Partlyf
Partlyf
Partlyf
Partlyf
No
No
No
No
No
No
Partlyf
Partlyf
Partlyf
No
No
Not sure
No
Partlyh
Yesb
No
No
No
Partlyh
Partlyh
Partlyh
No
Partlyh
No
Partlyh
Partlyh
No
Partly
No
Partlyh
Partlyh
No
No
No
Partlyc
No
No
No
No
Partlyc
Partlyc
Partlyc
No
Partlyc
No
Partlyc
No
Partlyc
Partlyc
No
No
No
No
+
+++
+
+
+
+
+
+
+
+
++
++
++
++
+++
++
+
+
+
++
++
+
Yes yes, sources of potential bias are presented; No no potential bias; Not sure not enough details were reported to make a decision (in some cases authors were
contacted); NA not applicable according to the study design or type of analyses used.
a
Not all required information about study attrition was provided.
b
A study does not address the possibility of confounding.
c
Some errors in analyses performed were observed: e.g. limited details about analyses.
d
Completeness of follow-up was not adequate.
e
Small sample size.
f
Detail information about measure used was not provided or used measure was not validated.
g
Analyses performed were not adequate.
h
Not all important covariates were included or exclusion criteria are not completed.
i
Baseline assessment performed after 1 month post-injury.
Identification
705
Screening
Eligibility
Included
Bushnik et al., 2008b; Cooper et al., 2009; Hillier et al., 1997; Wiart
et al., 2012; Kim et al., 1999; Haboubi et al., 2001; Olver et al., 1996;
Rees and Bellon, 2007; Meares et al., 2011). Main analyses featured
11 inception cohort studies with baseline assessment performed
within one-month post-injury (Lidvall et al., 1974; Ponsford et al.,
2012; De Leon et al., 2009; Lundin et al., 2006; Meares et al., 2011;
Mickeviciene et al., 2004; Norrie et al., 2010; van der Naalt et al.,
1999; Yang et al., 2009; McLean et al., 1993; Hutchinson et al.,
2009). Separate analyses of studies with baseline assessment after
one month included 11 studies (McLean et al., 1993; Sundstrom
et al., 2007; Sigurdardottir et al., 2009; Kempf et al., 2010; Driver
and Ede, 2009; Gemmell and Leathem, 2006; Bushnik et al., 2008a;
Jha et al., 2008; Kaiser et al., 2010; Khateb et al., 2005; Schoenberger
et al., 2001; Hou et al., 2012), among them six RCTs (Driver and Ede,
2009; Gemmell and Leathem, 2006; Jha et al., 2008; Kaiser et al.,
2010; Khateb et al., 2005; Schoenberger et al., 2001).
All 22 studies (Lidvall et al., 1974; Ponsford et al., 2012; De Leon
et al., 2009; Lundin et al., 2006; Meares et al., 2011; Mickeviciene
et al., 2004; Norrie et al., 2010; van der Naalt et al., 1999; Yang et al.,
2009; McLean et al., 1993; Sundstrom et al., 2007; Hutchinson et al.,
2009; Sigurdardottir et al., 2009; Kempf et al., 2010; Driver and Ede,
2009; Gemmell and Leathem, 2006; Bushnik et al., 2008a; Jha et al.,
2008; Kaiser et al., 2010; Khateb et al., 2005; Schoenberger et al.,
2001; Hou et al., 2012) were assessed as having Partly or No
on all bias criteria. Two studies (De Leon et al., 2009; Mickeviciene
et al., 2004) were of high quality (+++), six (Lidvall et al., 1974;
Lundin et al., 2006; Norrie et al., 2010; van der Naalt et al.,
1999; McLean et al., 1993; Sundstrom et al., 2007) were of good
706
2009; Gemmell and Leathem, 2006; Jha et al., 2008; Kaiser et al.,
2010; Schoenberger et al., 2001), two comprised patients with
moderate to severe TBI (Bushnik et al., 2008a; Khateb et al., 2005),
and two with mild TBI (Sundstrom et al., 2007; Hou et al., 2012).
The percentage of males ranged between 17%(Schoenberger
et al., 2001) and 85% (Kaiser et al., 2010), with a mean 62 19.2%
across samples. The mean age ranged from 31 years (Bushnik et al.,
2008a) to 55.2 years of age (Sundstrom et al., 2007), with a mean
39.9 6.6 years across studies. Mean TSI, across the ten studies, was
39.5 35.5 months (i.e. 1185 1065 days) and baseline assessment
times ranged from 2.6 months (Bushnik et al., 2008a) to 8.6 years
post-injury (Gemmell and Leathem, 2006).
3.5. Assessment of TBI
Considerable between-study variation was observed in TBI
diagnostic criteria and denitions, irrespective of TSI at baseline
assessment (Tables 13). Most studies (17/22) used a combinatorial
approach to conrm and assess TBI, using tools such as the Glasgow Coma Scale (GCS), duration of posttraumatic amnesia (PTA)
and loss of consciousness (LOC), and clinical evaluation (Lidvall
et al., 1974; Ponsford et al., 2012; De Leon et al., 2009; Lundin et al.,
2006; Meares et al., 2011; Mickeviciene et al., 2004; Norrie et al.,
2010; van der Naalt et al., 1999; Yang et al., 2009; McLean et al.,
1993; Hutchinson et al., 2009; Sigurdardottir et al., 2009; Gemmell
and Leathem, 2006; Bushnik et al., 2008a; Jha et al., 2008; Khateb
et al., 2005; Hou et al., 2012). Three studies (Sundstrom et al., 2007;
Driver and Ede, 2009; Schoenberger et al., 2001) used other methods, including patient report, description of damage and/or lesions
based on medical records, and diagnoses of referring professionals.
Two studies used GCS scores alone (Kempf et al., 2010; Kaiser et al.,
2010).
3.6. Methods used for assessing fatigue
707
708
Table 5
Fatigue measures and their corresponding scores at assessment.
Study
Bushnik et al. (2008b)
Injury type/severity
Assessment
Measure
Sev(BL)
Sev(t1 )
Sev(t2 )
Sev(t3 )
TBI/mod-sev
GFI
NR
23 10
17 11
20 11
3.4 1.5
2.9 1.6
3.2 1.8
FSS
BL: ED
t1 : 1 mo
t2 : 3 mos
t3 : 12 mos
SF-36v
1: 52.8 9.53
2: 50.4 10.48
NR
NR
1: 52.3 12.22
2: 49.6 11.83
TBI control/NR
POMS
fatigue-inertia
subscale
1.24 .61
1.29 .57
NA
NA
TBI control/NR
SF-36v
47.50 20.18
38.75 4.43
NA
NA
TBI/mild
BL: 96 h post-injury
t1 , t2 , t3 : 3 non-consecutive d over 2
wks
POMS
fatigue-inertia
subscale
4.3
6.8
4.4
MFIS
1:
46.56 19.28
2:
47.17 15.53
1:
45.22 11.82
2:
44.46 12.17
1:
38.65 16.09
2:
36.45 15.03
1:
39.36 15.61
2: 37.7 12.55
1: 35.63 20
2:
33.55 18.16
NA
1:
37.13 18.33
2:
36.91 14.08
NA
FSS
Brain injury/PTA 8 10 d
29-item fatigue
scale
132.6 27.3
126.1 32.3
NA
NA
Concussion/NR
BL: ED
t1 : 3 mos
t2 : 1 y
VAS fatigue
item
NR
50 28
50 30
NA
TBI/mild
t1 : 1 mo
t2 : 3 mos
t3 : 12 mos
SF-36 Vitality
NR
46.57 24.72
60.21 19.68
62.11 20.18
FSS
NR
3.99 1.53
3.29 1.44
3.20 1.39
TBI/mild
BL: ED post-injury
t1 : 1 wk
t2 : 3 mos
PCSC Checklist
NR
2.8
2.2
NA
Closed HI/mod-sev
MFI: Gen
MFI: Phys
MFI: Men
14.83 4.17
10.50 4.51
15.50 3.83
14.00 4.56
10.83 5.34
15.67 3.50
NA
NA
TBI/mild-sev
BL: ED
t1 : 3 mos
t2 : 12 mos
FSS
NR
NR
4.0 1.8
NA
BL, baseline; ED, emergency department; FSS, fatigue severity scale; GFI, global fatigue inventory; LOC, loss of consciousness; MFIS, modied fatigue impact scale; MFI, multidimensional fatigue inventory; HI, head injury; TBI,
traumatic brain injury; mos, months; NR, not reported; NA, not applicable; PCSC, post-concussion syndrome checklist; POMS, prole of moods scale; PTA, post-traumatic amnesia; sev, severity; SF-36 V, 36-item short form health
survey vitality subscale (from medical outcomes study); TBI, traumatic brain injury; VAS, visual analogue scale; wks, weeks; y, year.
(a)
6d
14d
33
5%
7%10 73.3%15
2d
(b)
30 d
10
31
27
10
709
90 d
30
32
8% 57% 74%
7092d
10
26
28
29
27
15
30
8%31
28.2%29 45%30
7d
60 d
180d
360d
90 d
648d
33%44
80%41
42%33
16%36 27%44
60%41
35%36
180d
690d
1080d
Fig. 3. (a) Reported frequencies of fatigue for studies with time zero 1-month post-injury. (b) Reported frequencies of fatigue for studies with time zero >1-month post-injury.
for two TBI subgroups (De Leon et al., 2009). Other researchers who
utilized the same standardized scales could not be compared on
the basis of their measurement of fatigue at different time points,
or missing data on scores (Table 5).
3.11. Impact of fatigue after TBI
One study where baseline assessment took place prior to one
month post-injury and one with baseline assessment at three
months post-injury investigated consequences of fatigue.
Table 4 shows lists the consequences signicantly associated
with fatigue. One study of moderate quality looked at the relationship of fatigue with persistent post-concussive symptoms
(Norrie et al., 2010), and one of fair quality looked at its association with the Glasgow outcome scale-extended (GOSE) total score
(Sigurdardottir et al., 2009).
Persistent post-concussive symptoms: Fatigue severity at one
week and three months predicted persistent post-concussive
symptoms at three months and six months, respectively, controlling for litigation, psychological/neurological disorders, and
substance abuse (Table 4) (Norrie et al., 2010).
GOSE total score: An association with the GOSE score was
found in Sigurdardottir et al.s study controlling for education, PTA,
intracranial pathology and relevant psychological tests in multivariate regression analysis models. In the mild TBI group, the FSS
total score was a signicant predictor of GOSE score (R2 = 0.47;
p < .001), explaining 23% of the total variance in GOSE score at one
year post-injury. Similar results were obtained for the moderate to
severe TBI group (R2 = 0.58; p < .001) (Table 4).
3.12. Associations of fatigue with other clinically important
variables
3.12.1. Studies with baseline assessment up to one month
post-injury
Lundin et al. (2006) found poor memory, sleep disturbance
and fatigue to be most commonly reported within their sample,
with early symptom overlap correlated with later results. Similarly,
Meares et al. (2011) found symptom overlap of fatigue, insomnia,
and irritability at ve days and three months post-injury, with some
710
4. Discussion
4.1. Factors associated with fatigue
When we sought evidence of a temporal relationship between
clinically important factors and fatigue we focused on: (1) TBI population characteristics (e.g. time since injury, severity of injury,
comorbid conditions, etc.) and (2) our outcome of interest (i.e.
fatigue) its frequency, severity, and denition, with the goal of
obtaining a set of risk factors that can be used for prognosis. Table 4
presents a descriptive summary of the available evidence. In summary, several potential risk factors for fatigue in TBI have been
investigated, including those related to demographics and socioeconomic status, injury severity, medical comorbidities, baseline
fatigue levels, genetic makeup, and physical and cognitive independence.
Fatigue at baseline, occurring at any time from injury through
the acute care course, was found to be a primary predictor of symptom chronicity in TBI of varying severities (Norrie et al., 2010).
Baseline fatigue was found to be one of the most powerful predictors of fatigue at follow-up (De Leon et al., 2009; Norrie et al., 2010).
Other studies on chronic fatigue syndrome show similar associations between long-lasting fatigue and fatigue at baseline (Cairns
and Hotopf, 1997; Nisenbaum et al., 2003; Kato et al., 2006), concurrent with the results of another study, where pre-stroke fatigue
was reported to be related to fatigue in the acute phase after stroke
(Lerdal et al., 2011). Despite reports of an impact of baseline fatigue
711
712
713
Fig. 4. Model for studying fatigue symptoms in patients with traumatic brain injury.
714
715
Liska, K., 2008. Drugs and the Human Body. Prentice Hall.
Lundin, A., De Boussard, C., Edman, G., Borg, J., 2006. Symptoms and disability until
3 months after mild TBI. Brain Inj. 20 (8), 799806.
Maher, A.R., Maglione, M., Bagley, S., Suttorp, M., Hu, J.H., Ewing, B., Wang, Z., Timmer, M., Sultzer, D., Shekelle, P.G., 2011. Efcacy and comparative effectiveness
of atypical antipsychotic medications for off-label uses in adults: a systematic
review and meta-analysis. JAMA 306 (12), 13591369.
Mathias, J.L., Alvaro, P.K., 2012. Prevalence of sleep disturbances, disorders, and
problems following traumatic brain injury: a meta-analysis. Sleep Med. 13 (7),
898905.
McAllister, T.W., 1994. Mild traumatic brain injury and the postconcussive syndrome. In: Silver, J.S., Yudofsky, S.C., Hahles, R.E. (Eds.), The Neuropsychiatry
of Traumatic Brain Injury. American Psychiatric Press, Washington, DC, pp.
357392.
McCrimmon, S., Oddy, M., 2006. Return to work following moderate-to-severe traumatic brain injury. Brain Inj. 20 (10), 10371046.
McLean, A., Dikmen, S.S., Temkin, N.R., 1993. Psychosocial recovery after head injury.
Arch. Phys. Med. Rehabil. 74, 10411046.
Meares, S., Shores, E.A., Taylor, A.J., Batchelor, J., 2011. The prospective course of postconcussion syndrome: the role of mild traumatic brain injury. Neuropsychology
25 (4), 454465.
Miaskowsky, C., 2004. Gender differences in pain, fatigue, and depression in patients
with cancer. J. Natl. Cancer Inst. Monogr. 32, 132143.
Mickeviciene, D., Schrader, H., Obelieniene, D., Surkiene, D., Kuniskas, R., et al., 2004.
A controlled prospective inception cohort study on the post-concussion syndrome outside the medicolegal context. Eur. J. Neurol. 11, 411419.
Middleboe, T., Andersen, H.S., Birket-Smith, M., Friis, M.L., 1992. Minor head injury:
impact on general health after 1 year, a prospective follow-up study. Acta Neurol.
Scand. 85 (1), 59.
Moher, D., Liberati, A., Tetzlaff, J., Altman, D.G., 2009. Preferable reporting items for
systematic reviews and meta-analyses for PRISMA statement. PLoS Med., 6.
Mollayeva, T., Kendzerska, T., Mollayeva, S., Shapiro, C.M., Colantonio, A., Cassidy,
J.D., 2013a. Fatigue in adults with traumatic brain injury: predictors and consequences. A systematic review of longitudinal study protocols. Syst. Rev. 11 (2),
25.
Mollayeva, T., Colantonio, A., Mollayeva, S., Shapiro, C.M., 2013b. Screening
for sleep dysfunction after traumatic brain injury. Sleep Med. 14 (12),
12351246.
Mollayeva, T., Kendzerska, T., Mollayeva, S., Colantonio, A., 2013c. Sleep apnea in
traumatic brain injury: understanding its impact on executive function. J. Sleep
Disorders Ther. 2, 129.
Nardone, R., Bergmann, J., Kunz, A., Caleri, F., Seidl, M., et al., 2011. Cortical excitability changes in patients with sleep-wake disturbances after traumatic brain
injury. J. Neurotrauma 28 (7), 11651671.
Nisenbaum, R., Jones, J., Unger, E., Reyes, M., Reyes, W.C., 2003. A population based
study of the chronic fatigue syndrome. Health Quality Life Outcomes 1, 49.
Norrie, J., Heitger, M., Leathem, J., Anderson, T., Jones, R., et al., 2010. Mild traumatic
brain injury and fatigue: a prospective longitudinal study. Brain Inj. 24 (1314),
15281538.
OHara, R., Schrodek, C., Kraemer, H., Kryla, N., Cao, C., 2005. Nocturnal sleep
apneahypopnea is associated with lower memory performance in APOE
epsilon4 carriers. Neurology 65, 642644.
Olver, J.H., Ponsford, J.L., Curran, C.A., 1996. Outcome following traumatic brain
injury: a comparison between 2 and 5 years after injury. Brain Inj. 10 (11),
841848.
Penning, R., McKinney, A., Verster, J.C., 2012. Alcohol hangover symptoms and their
contribution to the overall hangover severity. Alcohol Alcohol. 47 (3), 248252.
Ponsford, J., Cameron, P., Fitzgerald, M., Grant, M., Mickocka-Walus, A., 2011. Longterm outcomes after uncomplicated mild traumatic brain injury: a comparison
with trauma controls. J. Neurotrauma 28, 937946.
Ponsford, J.L., Ziino, C., Parcell, D.L., Shekleton, J.A., Roper, M., et al., 2012. Fatigue
and sleep disturbance following traumatic brain injury their nature, causes,
and potential treatments. J. Head Trauma Rehabil. 27 (3), 224233.
Prins, J.B., van der Meer, J.W., Bleijenberg, G., 2006. Chronic fatigue syndrome. Lancet
367, 346.
Rees, R.J., Bellon, M.L., 2007. Postconcussion syndrome ebb and ow: longitudinal
effects and management. Neurorehabilitation 22, 229242.
Rhodes, C., 2012. Opioids: is it time to change? Pain Pract. 22 (1), 4346.
Rohsenow, D.J., Howland, J., Minsky, S.J., Greese, J., Almeida, A., et al., 2007. The
acute hangover scale: a new measure of immediate hangover symptoms. Addict.
Behav. 32 (6), 13141320.
Schillings, M.L., Kalkman, J.S., Lannsen, H.H., van Engelen, B.M., Bleijenberg, G., et al.,
2007. Experienced and physiological fatigue in neuromuscular disorders. Clin.
Neurophysiol., 292300.
Schmitt, J.A., Kruizinga, M.J., Riedel, W.J., 2001. Non-serotonergic pharmacological proles and associated cognitive effects of serotonin reuptake inhibitors.
J. Psychopharmacol. 15 (3), 173179.
Schoenberger, N.E., Shieett, S.C., Esty, M.L., Ochs, R.J., Matheis, R.J., 2001. Flexyx
neurotherapy system in the treatment of traumatic brain injury: an initial evaluation. J. Head Trauma Rehabil. 16 (3), 260274.
Shukka, D., Devi, B.I., 2011. Outcome measures for traumatic brain injury. Clin. Neurol. Neurosurg. 113, 435441.
Siebern, A.T., Guilleminault, C., 2012. Sleepiness and fatigue following traumatic
brain injury: a clear relationship? Sleep Med. 13 (6), 559560.
2013. Scottish Intercollegiate Guidelines Network Published Guidelines, Retrieved
from: http://www.sign.ac.uk.guidelines/ (24.09.13).
716
Sigurdardottir, S., Andelic, N., Roe, C., Schanke, A.-K., 2009. Cognitive recovery and
predictors of functional outcome 1 year after traumatic brain injury. J. Intern.
Neuropsychol. Soc. 15, 740750.
Slavin, R.E., 1995. Best evidence synthesis: an intelligent alternative to metaanalysis. J. Clin. Epidemiol. 48, 918.
Stepanski, E., 2002. The effect of sleep fragmentation on daytime function. Sleep 25,
268276.
Sundstrom, A., Nilsson, L.-G., Cruts, M., Adolfsson, R., van Broeckhaun, C., Nyberg,
L., 2007. Fatigue before and after mild traumatic brain injury: prepostinjury comparisons in relation to apolipoprotein E. Brain Inj. 21 (10),
10491054.
van der Naalt, J., van Zomeren, A.H., Sluiter, W.J., Minderhoud, J.M., 1999. One year
outcome in mild to moderate head injury: the predictive value of acute injury
characteristics related to complaints and return to work. J. Neurol. Neurosurg.
Psychiatry 66, 207213.
van Rein, N., Cannegieter, S.C., Rosendaal, F.R., Reitsma, P.H., Lijfering, W.M., 2014.
Suspected survivor bias in case-control studies: stratify on survival time and use
a negative control. J. Clin. Epidemiol. 67 (2), 232235.
Ware, J.E., 1992. The MOS 36-item short form health survey (SF-36): conceptual
framework and item selection. Med. Care, 473483.
Wiart, L., Richer, E., Destaillats, J.M., Joseph, P.A., Dehail, P., Mazaux, J.M., 2012.
Psychotherapeutic follow up of our patients with traumatic brain injury: preliminary results of an individual neurosystemic approach. Ann. Phys. Rehabil.
Med. 55, 375387.
World Health Organization, 2002. Projection of Mortality and Burden of Disease to
2030. Death by Income Group, Geneva.
Yang, C.C., Hua, M.S., Tu, Y.K., Huang, S.-J., 2009. Early clinical characteristics of
patients with persistent post-concussion symptoms: a prospective study. Brain
Inj. 23 (4), 299306.
Yennurajalingam, S., Bruera, E., 2007. Palliative management of fatigue at the close
of life: it feels like my body is just worn out. JAMA 297 (3), 295304 (future
readings).
Zaben, M., El Ghoul, W., Belli, A., 2013. Post-traumatic head injury pituitary dysfunction. Disabil. Rehabil. 35 (6), 522525.
Ziino, C., Ponsford, J., 2006. Selective attention decits and subjective fatigue following traumatic brain injury. Neuropsychology 20 (3), 383390.